TGA Regulatory Changes1st of June 2018
As of the 1st of June 2018 there are going to be some changes to 3 SARM compounds.
SR9009 is a synthetic Rev-Erb ligand it is a very unique compound. It has the ability to greatly influence a lot of regulatory mechanisms such as circadian rhythms, lipid and glucose metabolism, fat-storing cells, as well as macrophages. SR9009 will allow the user to lose fat and drastically increase endurance.
On April 10th 2018 TGA accounanced that SR9009 will be rescheduled from a Schedule 4 to a Schedule 4 Appendix D
MK – 677
Technically not a SARM, but always gets thrown into the same category. MK-677 promotes the secretion of the growth hormone (GH) and increases insulin-like growth factor 1 (IGF1). MK677 increases growth hormone levels, by mimicking the action of the hormone ghrelin, and binding to one of the ghrelin receptors (GHSR) in the brain. Activated GHSR stimulates growth hormone release from the brain.
On April 10th 2018 TGA accounanced that MK-677 will be rescheduled from a Schedule 4 to a Schedule 4 Appendix D
What does that mean for you ?
If you purchase SR9009 or MK677 from Human Enhancement Clinic there is nothing you need to worry about. We already follow all the regulatory requirements for Schedule 4 medications.
Cardarine (GW-501516) is compound that binds to the PPAR receptor. When binding to the PPAR receptor, recruits what is called the coactivator PGC-1α enzyme, which then increases the expression of genes involved in the expenditure of energy (cardarine activates the same genetic pathways that are involved in exercise). Subject treated with Cardarine were shown to have increased fatty acid metabolism and increased protection against obesity from eating a bad diet, as well as an increased protection from type-2 diabetes.
On April 10th 2018 TGA accounanced that GW501516 will be rescheduled from a Schedule 4 to a Schedule 10.
Human Enhancement Clinic will no longer be able to prescribe GW501516 after June 1st 2018